1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd

BBSE:SUDARSHAN
32.57
INR
-1.23
(-3.64%)
5.83BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
4.26
6.79
10.71
6.15
8.03
14.84
35.9
192.61
209.86
292.14
- -
Basic EPS, GAAP
0.01
0.06
0.18
0.05
0.11
0.22
0.55
4.76
6.2
9.68
- -
Free Cash Flow per Basic Share
-0.12
- -
-0.08
0.03
0.12
-0.16
-2.24
3.22
-22.26
-29.67
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.3
- -
- -
- -
Book Value per Share
2.47
6.58
14.43
0.83
0.94
3.05
4.2
4.7
5.47
6.44
- -
Tangible Book Value per Share
2.46
6.56
14.41
0.82
0.93
3.04
4.16
4.5
5.28
5.81
- -
Basic Weighted Avg Shares
130
130
130
241
241
241
129
24
24
24
240
Sales/Revenue/Turnover
554
881
1,391
1,480
1,934
3,571
4,613
4,635
5,050
7,031
- -
Operating Margin (%)
1.14
2.4
3.63
3.42
3.32
2.84
3.13
4.65
6.65
6.76
- -
Depreciation Expense
1
1
1
3
7
9
9
12
28
38
- -
Net Income, GAAP
2
7
23
13
27
52
70
115
149
233
- -
Effective Tax Rate (%)
39.92
25.18
28.12
25.68
25.27
26.44
25.9
24.78
25.24
23.47
- -
Profit Margin (%)
0.28
0.84
1.69
0.86
1.38
1.47
1.53
2.47
2.96
3.31
- -
Working Capital
38
51
138
125
164
270
801
706
668
341
- -
LT Debt
24
28
45
41
53
49
128
117
133
286
- -
Total Equity
32
85
187
198
225
298
1,010
1,130
1,317
1,563
- -
Return on Invested Capital (%)
- -
11.37
13.96
9
10.23
13
10.61
9.16
8.83
9.96
- -
Return on Capital (%)
- -
11.15
12.94
8.54
10.34
12.92
10.68
9.79
9.66
10.89
- -
Return on Common Equity (%)
- -
12.59
17.21
6.61
12.62
20.08
10.76
10.71
12.2
16.25
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
2,564
- -
LT Borrowings
- -
284
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
241
241
250
Market Capitalization
6,630
5,834
9,362

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
4,903
- -
Cash, Cash Equivalents & STI
- -
109
- -
Accounts Receivable, Net
- -
2,333
- -
Inventories
- -
2,187
- -
Total Current Liabilities
- -
4,561
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
2,564
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
63.71%
18.65%
Free Cash Flow
- -
-93.64%
33.28%
Net Income, GAAP
- -
55.95%
56.09%
Sales/Revenue/Turnover
- -
32.5%
39.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
992
1,286
1,157
1,616
5,050
2026
1,453
- -
1,680
2,209
7,031
2027
1,744
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.05
0.3
0.12
0.29
6.2
2026
0.16
- -
0.18
0.48
9.68
2027
0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hemal Vasantrai Mehta
Full Time Employees
60
Sector
Health technology
Industry
Pharmaceuticals: major
Address
301, Aura Biplex Mumbai MA India 400092
IPO Date
Mar 22, 2023
Website
sudarshanpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sudarshan Pharma Industries Ltd. is a pharmaceutical manufacturing company primarily engaged in the production, marketing, and distribution of pharmaceutical formulations and products. The company offers a broad portfolio including generic pharmaceuticals, active pharmaceutical ingredients (APIs), and contract manufacturing services. Its product categories encompass tablets, capsules, injectables, ointments, syrups, and nutritional supplements, serving diverse therapeutic areas. Sudarshan Pharma operates predominantly in the Indian pharmaceutical sector while expanding its presence in international markets. Founded in 1984 and headquartered in Mumbai, India, the company caters to a wide range of healthcare providers, hospitals, and pharmacies through its subsidiaries and business segments. In recent developments over the last 1-2 years, Sudarshan Pharma has pursued strategic partnerships and expanded its product offerings to include innovative formulations and enhanced contract manufacturing capabilities. The company has also embarked on targeting emerging markets with an emphasis on biologics and biosimilar products, signaling a major shift towards diversified pharmaceutical segments beyond traditional generics. These expansions are part of its broader strategy to strengthen its global footprint and operational scale. No recent name changes or major reorganizations have been reported, but the company continues to invest in research and development to support its evolving product pipeline and market reach. Sudarshan Pharma Industries Ltd. operates within the pharmaceutical industry with business segments including formulation development, contract manufacturing, and research services. Its target markets include domestic Indian healthcare providers and expanding international customers across Asia, Africa, and other emerging regions. The company's headquarters is located in Mumbai, India, and it maintains several subsidiaries to support manufacturing and distribution activities. This comprehensive approach enables Sudarshan Pharma to maintain competitive positioning in both domestic and global pharmaceutical markets.